Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI)

Price$4.84

Value ScoreC

Growth ScoreD

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)17.67%

Price vs S&P 500 (4W)20.51%

VGM Score57.43

Market Capitalization$712.45M

All Metrics

P/CF (Annual)121.94x

Book Value / Share (Quarterly)$0.82

P/TBV (Annual)13.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-40.53%

Cash Flow / Share (Quarterly)$-0.20

Price vs S&P 500 (YTD)37.23%

Gross Margin (TTM)29.29%

Net Profit Margin (TTM)-51.07%

EPS (TTM)$-0.72

10-Day Avg Trading Volume2.67M

EPS Excl Extra (TTM)$-0.72

Revenue Growth (5Y)-8.15%

EPS (Annual)$-0.91

ROI (Annual)-24.43%

Gross Margin (Annual)18.30%

Net Profit Margin (5Y Avg)-23.96%

Cash / Share (Quarterly)$0.64

Revenue Growth QoQ (YoY)40.53%

ROA (Last FY)-16.97%

Revenue Growth TTM (YoY)-15.35%

EBITD / Share (TTM)$-1.11

ROE (5Y Avg)-7.32%

Operating Margin (TTM)-82.19%

Cash Flow / Share (Annual)$-0.28

P/B Ratio3.37x

P/B Ratio (Quarterly)3.45x

Net Income / Employee (Annual)$-300,600

EV / Revenue (TTM)3.99x

Net Interest Coverage (TTM)-14.11x

ROA (TTM)-12.95%

EV / EBITDA (TTM)9.35x

EPS Incl Extra (Annual)$-0.91

Current Ratio (Annual)6.60x

Quick Ratio (Quarterly)4.68x

3-Month Avg Trading Volume1.90M

52-Week Price Return126.76%

EV / Free Cash Flow (Annual)3.16x

Revenue / Employee (TTM)$470,600

Tangible BV / Share (Quarterly)$0.26

P/S Ratio (Annual)3.84x

Asset Turnover (Annual)0.24x

52-Week High$5.00

Operating Margin (5Y Avg)-16.92%

EPS Excl Extra (Annual)$-0.91

CapEx CAGR (5Y)-12.34%

26-Week Price Return31.25%

Quick Ratio (Annual)5.40x

13-Week Price Return33.80%

Total Debt / Equity (Annual)1.52x

Current Ratio (Quarterly)5.91x

Enterprise Value$817.41M

Revenue / Share Growth (5Y)3.13%

Asset Turnover (TTM)0.25x

Book Value / Share Growth (5Y)19.28%

Revenue / Employee (Annual)$427,000

Inventory Turnover (Annual)3.35x

Pretax Margin (Annual)-126.50%

Cash / Share (Annual)$0.85

3-Month Return Std Dev70.53%

Gross Margin (5Y Avg)54.38%

Net Income / Employee (TTM)$-240,400

EBITDA Interim CAGR (5Y)-50.59%

ROE (Last FY)-61.58%

Net Interest Coverage (Annual)-10.89x

EPS Basic Excl Extra (Annual)$-0.91

P/FCF (TTM)168.51x

Receivables Turnover (TTM)6.61x

EV / Free Cash Flow (TTM)38.73x

Total Debt / Equity (Quarterly)1.28x

EPS Incl Extra (TTM)$-0.72

Receivables Turnover (Annual)5.80x

ROI (TTM)-19.20%

P/S Ratio (TTM)3.48x

Pretax Margin (5Y Avg)23.06%

Revenue / Share (Annual)$1.29

Tangible BV / Share (Annual)$0.24

Price vs S&P 500 (52W)98.61%

Year-to-Date Return48.62%

5-Day Price Return10.53%

EPS Normalized (Annual)$-0.91

ROA (5Y Avg)-4.04%

Net Profit Margin (Annual)-70.41%

Month-to-Date Return0.63%

Cash Flow / Share (TTM)$0.75

EBITD / Share (Annual)$-1.47

Operating Margin (Annual)-115.89%

LT Debt / Equity (Annual)1.35x

ROI (5Y Avg)-3.36%

LT Debt / Equity (Quarterly)1.11x

EPS Basic Excl Extra (TTM)$-0.72

P/TBV (Quarterly)10.96x

P/B Ratio (Annual)3.91x

Inventory Turnover (TTM)3.21x

Pretax Margin (TTM)-92.22%

Book Value / Share (Annual)$0.83

Price vs S&P 500 (13W)23.13%

Beta0.69x

P/FCF (Annual)11.74x

Revenue / Share (TTM)$1.40

ROE (TTM)-44.72%

52-Week Low$1.99

vGradeC

gGradeD

mGradeA

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.01est. -0.05

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.82

3.88

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
MRVIMaravai LifeSciences Holdings, Inc. Class A Common Stock	C	D	A	$4.84
LLYEli Lilly & Co.	D	B	B	$1078.78
JNJJohnson & Johnson	C	C	C	$223.24
ABBVABBVIE INC.	D	C	C	$217.13
MRKMerck & Co., Inc.	C	C	C	$114.70
AZNAstraZeneca PLC	D	B	C	$176.28
NVSNovartis AG	C	C	C	$143.66
NVONovo-Nordisk A/S	B	B	B	$42.00
ABTAbbott Laboratories	C	C	D	$86.99
PFEPfizer Inc.	B	C	C	$25.34
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$32.83

About

Maravai LifeSciences provides critical enabling technologies and services for pharmaceutical and biotechnology companies developing drugs, vaccines, and diagnostics. The company operates through two segments: TriLink, which supplies nucleic acid products including mRNA and oligonucleotides; and Cygnus, which provides biologics safety testing and quality assurance solutions. Its products serve customers throughout drug development, manufacturing, and quality assurance processes.